

Overview: Unmet needs in the treatment of CHB

Chun-Jen Liu

**Professor, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine
Visiting staff, Department of Internal Medicine and Hepatitis Research Center, National Taiwan University Hospital**

In the last decade, many new data on the natural history and treatment of chronic HBV infection have become available. However, there remain unmet needs regarding the treatment of chronic hepatitis B.

We need new drugs or strategies towards more effective management of chronic hepatitis B. Several novel therapies aiming for cure of HBV infection have just been developed; and some are tested in pre-clinical or early clinical trials.

As for current available anti-HBV agents, different strategies of adding-on or switching to Peg-IFN in patients initially receiving NUC therapy are tested in several clinical trials, and the results seem promising. The goals are to enhance efficacy of anti-HBV activity, increase post-treatment durability of response and shorten treatment duration.

Besides, several host and viral factors have been identified to predict the treatment outcomes. These biomarkers would help the development of individualized therapy of chronic hepatitis B.